令和 7 年度 第 81 回 大学院セミナー

2026 年 3 月 4 日

分 野 名 (責任者名)(内線)	医歯薬学総合研究科 放射線医療科学専攻 血液内科学分野（原研内科） 責任者名 宮﨑泰司 内線 7111
演 題	原研研究集会 GENKEN research seminar
講 師 等	原研内科 教授 宮﨑泰司 先生 Yasushi MIYAZAKI, professor, Dept. of Hematology
概要	**Comparison of myelodysplastic syndromes (MDS) among atomic bomb survivors and therapy-related MDS** Myelodysplastic syndromes (MDS) is hematologic malignancy caused by the accumulation of genomic mutations in hematopoietic stem cells and are most commonly observed in the elderly. It is well known that the risk of developing MDS increases after chemotherapy and/or radiotherapy; such cases are referred to as therapy-related MDS. Among atomic bomb survivors, previous epidemiological studies have demonstrated a dose-dependent increase in the incidence of MDS, suggesting that atomic bomb radiation may represent one of the etiological factors for MDS. Although therapy-related MDS involves exposure to radiation (and/or chemotherapeutic agents) as an external factor, and MDS among survivors also shares radiation exposure as a common external insult, direct comparisons between these two conditions have not been sufficiently investigated. In this study, we retrospectively collected cases of MDS diagnosed at Nagasaki University Hospital and its affiliated institutions and performed a clinical comparison between MDS among survivors had a significantly better prognosis than those with therapy-related MDS. Furthermore, balanced chromosomal abnormalities were significantly more frequent in atomic bomb survivor–associated MDS.
開 催 日 時	2026 年 3 月 18 日(水) 17:30 ～ 18:30
開 催 方 法	Zoom
備 考	受講を希望する場合は、ID・パスワードをお教えしますので、必ずご連絡ください。（内線 7111 or Email: k-seven@nagasaki-u.ac.jp） If you would like to participate in this seminar and need Zoom ID and Password, please contact k-seven@nagasaki-u.ac.jp.

□先端医療科学特論（基礎編） □先端医療科学特論（臨床編）
□先端新興感染症病態制御学特論 ■先端放射線医療科学特論
□日本語(Japanese) ■英語(English)
□対面(Face to face) ■オンライン(Online)